508 related articles for article (PubMed ID: 29473493)
1. Current Limitations in the Treatment of Parkinson's and Alzheimer's Diseases: State-of-the-Art and Future Perspective of Polymeric Carriers.
Tonda-Turo C; Origlia N; Mattu C; Accorroni A; Chiono V
Curr Med Chem; 2018; 25(41):5755-5771. PubMed ID: 29473493
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic Strategies for Alzheimer's and Parkinson's Diseases by Means of Drug Delivery Systems.
Cunha S; Amaral MH; Lobo JM; Silva AC
Curr Med Chem; 2016; 23(31):3618-3631. PubMed ID: 27554805
[TBL] [Abstract][Full Text] [Related]
3. Advances in nanomedicine for the treatment of Alzheimer's and Parkinson's diseases.
Hernando S; Gartziandia O; Herran E; Pedraz JL; Igartua M; Hernandez RM
Nanomedicine (Lond); 2016 May; 11(10):1267-85. PubMed ID: 27077453
[TBL] [Abstract][Full Text] [Related]
4. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs.
Agrawal M; Saraf S; Saraf S; Antimisiaris SG; Chougule MB; Shoyele SA; Alexander A
J Control Release; 2018 Jul; 281():139-177. PubMed ID: 29772289
[TBL] [Abstract][Full Text] [Related]
5. Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.
Farr AC; Xiong MP
Mol Pharm; 2021 Feb; 18(2):593-609. PubMed ID: 32926630
[TBL] [Abstract][Full Text] [Related]
6. Nanocomposites for neurodegenerative diseases: hydrogel-nanoparticle combinations for a challenging drug delivery.
Giordano C; Albani D; Gloria A; Tunesi M; Rodilossi S; Russo T; Forloni G; Ambrosio L; Cigada A
Int J Artif Organs; 2011 Dec; 34(12):1115-27. PubMed ID: 22198597
[TBL] [Abstract][Full Text] [Related]
7. Nanotechnology-based Drug Delivery for Alzheimer's and Parkinson's Diseases.
Nguyen-Thi PT; Ho TT; Nguyen TT; Vo GV
Curr Drug Deliv; 2024; 21(7):917-931. PubMed ID: 37424345
[TBL] [Abstract][Full Text] [Related]
8. Surfactants, not size or zeta-potential influence blood-brain barrier passage of polymeric nanoparticles.
Voigt N; Henrich-Noack P; Kockentiedt S; Hintz W; Tomas J; Sabel BA
Eur J Pharm Biopharm; 2014 May; 87(1):19-29. PubMed ID: 24607790
[TBL] [Abstract][Full Text] [Related]
9. Alzheimer's Disease and Parkinson's Disease: A Review of Current Treatment Adopting a Nanotechnology Approach.
Trompetero A; Gordillo A; Del Pilar MC; Cristina VM; Bustos Cruz RH
Curr Pharm Des; 2018; 24(1):22-45. PubMed ID: 28847307
[TBL] [Abstract][Full Text] [Related]
10. Nano Carrier Drug Delivery Systems for the Treatment of Neuropsychiatric Disorders: Advantages and Limitations.
Zorkina Y; Abramova O; Ushakova V; Morozova A; Zubkov E; Valikhov M; Melnikov P; Majouga A; Chekhonin V
Molecules; 2020 Nov; 25(22):. PubMed ID: 33202839
[TBL] [Abstract][Full Text] [Related]
11. Nanotechnology-based delivery of therapeutics through the intranasal pathway and the blood-brain barrier for Alzheimer's disease treatment.
Boyetey MB; Choi Y; Lee HY; Choi J
Biomater Sci; 2024 Apr; 12(8):2007-2018. PubMed ID: 38456516
[No Abstract] [Full Text] [Related]
12. Nanotechnology-based drug delivery systems for the treatment of Alzheimer's disease.
Fonseca-Santos B; Gremião MP; Chorilli M
Int J Nanomedicine; 2015; 10():4981-5003. PubMed ID: 26345528
[TBL] [Abstract][Full Text] [Related]
13. Nano carriers for drug transport across the blood-brain barrier.
Li X; Tsibouklis J; Weng T; Zhang B; Yin G; Feng G; Cui Y; Savina IN; Mikhalovska LI; Sandeman SR; Howel CA; Mikhalovsky SV
J Drug Target; 2017 Jan; 25(1):17-28. PubMed ID: 27126681
[TBL] [Abstract][Full Text] [Related]
14. Potential Gene Therapy Towards Treating Neurodegenerative Disea ses Employing Polymeric Nanosystems.
Bangde P; Atale S; Dey A; Pandit A; Dandekar P; Jain R
Curr Gene Ther; 2017; 17(2):170-183. PubMed ID: 28494742
[TBL] [Abstract][Full Text] [Related]
15. The Therapeutic Benefits of Intravenously Administrated Nanoparticles in Stroke and Age-related Neurodegenerative Diseases.
Farhoudi M; Sadigh-Eteghad S; Mahmoudi J; Farjami A; Mahmoudian M; Salatin S
Curr Pharm Des; 2022; 28(24):1985-2000. PubMed ID: 35676838
[TBL] [Abstract][Full Text] [Related]
16. Review of Current Strategies for Delivering Alzheimer's Disease Drugs across the Blood-Brain Barrier.
Wong KH; Riaz MK; Xie Y; Zhang X; Liu Q; Chen H; Bian Z; Chen X; Lu A; Yang Z
Int J Mol Sci; 2019 Jan; 20(2):. PubMed ID: 30658419
[TBL] [Abstract][Full Text] [Related]
17. Targeting the central nervous system: From synthetic nanoparticles to extracellular vesicles-Focus on Alzheimer's and Parkinson's disease.
Hernando S; Santos-Vizcaíno E; Igartua M; Hernandez RM
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2023; 15(5):e1898. PubMed ID: 37157144
[TBL] [Abstract][Full Text] [Related]
18. Design, characterization, and evaluation of intranasal delivery of ropinirole-loaded mucoadhesive nanoparticles for brain targeting.
Jafarieh O; Md S; Ali M; Baboota S; Sahni JK; Kumari B; Bhatnagar A; Ali J
Drug Dev Ind Pharm; 2015; 41(10):1674-81. PubMed ID: 25496439
[TBL] [Abstract][Full Text] [Related]
19. Nanomedicine against Alzheimer's and Parkinson's Disease.
Tandon A; Singh SJ; Chaturvedi RK
Curr Pharm Des; 2021; 27(12):1507-1545. PubMed ID: 33087025
[TBL] [Abstract][Full Text] [Related]
20. Blood-brain barrier pathology in Alzheimer's and Parkinson's disease: implications for drug therapy.
Desai BS; Monahan AJ; Carvey PM; Hendey B
Cell Transplant; 2007; 16(3):285-99. PubMed ID: 17503739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
